Utah Medical Products, Inc.

Utah Medical Products, Inc.

UTMDยทNASDAQ

$66.95

+0.60%
HealthcareMedical - Instruments & Supplies

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

At a Glance

Live Snapshot
Market Cap$213.17M
EPS3.4100
P/E Ratio19.63
Earnings Date07/23/2026
utmd

Utah Medical Products, Inc. Street Expectations Map

UTMD ยท NASDAQ

No Target Data

No analyst price targets available for utmd.

utmd

Utah Medical Products, Inc. Forward Estimates of Revenue

UTMD ยท NASDAQ
Latest Revenue
38.52M
FY 2025
Avg Estimate
38.34M
FY 2013
Estimate Range
30.67M - 46.01M
Analyst Spread

Forward Growth Analysis

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread40%

Wide estimate range reveals significant forecast uncertainty and potential volatility.

OutlookCautious

Analyst skepticism evidentโ€”carefully evaluate risks before investment decisions.

utmd

Utah Medical Products, Inc. Forward Estimates of Net Income

UTMD ยท NASDAQ
Latest Net Income
11.29M
FY 2025
Avg Estimate
9.66M
FY 2013
Estimate Range
7.73M - 11.60M
Analyst Spread

Forward Growth Analysis

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread40%

Wide estimate range reveals significant forecast uncertainty and potential volatility.

OutlookCautious

Analyst skepticism evidentโ€”carefully evaluate risks before investment decisions.

utmd

Utah Medical Products, Inc. Forward Estimates of EPS

UTMD ยท NASDAQ
Latest EPS
3.41
FY 2025
Avg Estimate
$2.31
FY 2013
Estimate Range
$1.85 - $2.77
Analyst Spread

Forward Growth Analysis

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread40%

Wide estimate range reveals significant forecast uncertainty and potential volatility.

OutlookCautious

Analyst skepticism evidentโ€”carefully evaluate risks before investment decisions.

utmd

Utah Medical Products, Inc. Forward Estimates of EBIT

UTMD ยท NASDAQ
Latest EBIT
14.11M
FY 2025
Avg Estimate
12.88M
FY 2013
Estimate Range
10.30M - 15.45M
Analyst Spread

Forward Growth Analysis

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread40%

Wide estimate range reveals significant forecast uncertainty and potential volatility.

OutlookCautious

Analyst skepticism evidentโ€”carefully evaluate risks before investment decisions.

utmd

Utah Medical Products, Inc. Forward Estimates of EBITDA

UTMD ยท NASDAQ
Latest EBITDA
17.06M
FY 2025
Avg Estimate
15.33M
FY 2013
Estimate Range
12.26M - 18.39M
Analyst Spread

Forward Growth Analysis

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread40%

Wide estimate range reveals significant forecast uncertainty and potential volatility.

OutlookCautious

Analyst skepticism evidentโ€”carefully evaluate risks before investment decisions.

utmd

Utah Medical Products, Inc. Forward Estimates of SG&A Expense

UTMD ยท NASDAQ
Latest SG&A Expense
7.80M
FY 2025
Avg Estimate
7.72M
FY 2013
Estimate Range
6.18M - 9.26M
Analyst Spread

Forward Growth Analysis

Analyst Coverage7 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread40%

Wide estimate range reveals significant forecast uncertainty and potential volatility.

OutlookCautious

Analyst skepticism evidentโ€”carefully evaluate risks before investment decisions.

utmd

Utah Medical Products, Inc. Insider Positioning

UTMD ยท NASDAQ

During the last 12 months, insiders have sold $650K worth of UTMD shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

10.0K

640.90K

Net Activity

-641K

-$641K

9-12 Months

Bought

0

0.00

Sold

150

9.17K

Net Activity

-9K

-$9K

Top Buyers

No buying activity

Top Sellers

1
LC

Leigh Carrie

Director

10.0K sharesโ€ข1 transactions

$641K

2
RPO

Richins Paul O

Director

100 sharesโ€ข1 transactions

$6K

3
KB

Koopman Brian

Officer: Principal Financial Officer

50 sharesโ€ข1 transactions

$3K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $650K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Insider Participation

High Selling

3 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.